<DOC>
	<DOCNO>NCT03023059</DOCNO>
	<brief_summary>From 3 large patient database , patient diagnose AMD never take levodopa ( L-DOPA ) contain medication mean age diagnosis 71 year . Patients treat L-DOPA contain medication mean age diagnosis AMD 79 year . L-DOPA bind GPR143 retinal pigment epithelium , release PEDF , protect retina downregulates VEGF , cause neovascularization . The Investigators evaluate safety tolerability carbidopa-levodopa patient Neovascular AMD , measure effect visual acuity retinal abnormality due `` wet '' ( neovascular ) AMD . The Investigators evaluate safety tolerability carbidopa-levodopa patient Neovascular AMD already treatment anti-VEGF intraocular injection , measure effect visual acuity , retinal abnormality due `` wet '' AMD , document number anti-VEGF injection require study .</brief_summary>
	<brief_title>Dose Ranging Study Carbidopa-levodopa</brief_title>
	<detailed_description>Age-related macular degeneration ( AMD ) common cause blindness , individual age 50 , develop world . AMD become common people age , common lightly pigmented individual . AMD appear common patient Parkinson 's Disease , without . The AREDS nutritional supplement effective slow progress intermediate AMD ( 5 ) . Most AMD `` dry AMD '' , progress relatively slowly may impair vision , usually lead legal blindness . There two form AMD , `` wet AMD '' geographic atrophy ( GA ) , cause profound vision loss . In aggregate occur 25 % patient AMD . Wet AMD due new growth abnormal blood vessel retina . The new blood vessel believe due excessive release vascular endothelial growth factor ( VEGF ) retinal pigment epithelium ( RPE ) cell . Wet AMD effectively treat intraocular injection VEGF inhibitor . Geographic Atrophy , form advance AMD , represent focal death RPE cell overlie neurosensory retina . There current treatment GA . It suspect GA due part localize inflammatory response , damage RPE cell loss RPE cell function . It may also speculate stimulation RPE cell release potent neurotrophic factor , pigment epithelium derive factor ( PEDF ) may slow progression GA . In 2008 , Dr. Brian McKay identify receptor , G protein couple receptor # 143 ( GPR143 ) , surface RPE cell discover L-DOPA natural ligand stimulator GPR143 . Dr McKay show treatment RPE cell exogenous L-DOPA result release additional PEDF . In subsequent work Dr McKay 's group also show L-DOPA stimulation PEDF RPE cell also associate decrease VEGF . Thus , Dr McKay hypothesize exogenous L-DOPA may prevent onset AMD progression wet AMD . In 2015 , Dr McKay associate publish paper show patient , treat L-DOPA , delay onset AMD 8 year , compare patient treat L-DOPA . In addition , AMD go develop wet AMD , 5 year later history L-DOPA treatment . L-DOPA intermediate pigmentation pathway . Dr McKay associate suggest reason darkly pigment race get AMD nearly frequently light pigmented race , produce pigment , thus L-DOPA stimulate GPR143 RPE cell . According hypothesis , stimulate RPE cell release PEDF decrease VEGF , together responsible protective effect . Pharmacology L-DOPA carbidopa : L-DOPA form 3-hydroxylation tyrosine tyrosine-3-monooxygenase ( tyrosinase ) . ( 18 ) The primary metabolic pathway L-DOPA decarboxylation amino acid decarboxylase dopamine , responsible , , pharmacologic effect toxicity . When carbidopa administer L-DOPA , systemic level L-DOPA double central nervous system ( CNS ) L-DOPA increase 1 % administer dose 4 % . Levodopa freely pass systemic circulation retina brain , dopamine carbidopa . Adverse event markedly decrease carbidopa administer L-DOPA , systemic level toxic metabolite L-DOPA , dopamine , markedly reduce . In patient , 25 mg carbidopa sufficient control side effect 100 mg L-DOPA , primarily nausea , 90 % . L-DOPA natural ligand GPR143 RPE cell . The Investigators ' intent increase L-DOPA available RPE surface receptor ( GPR 143 ) minimize peripheral toxicity . This concept unique , use L-DOPA rely CNS conversion L-DOPA dopamine , order produce desire effect . Pathogenesis Neovascular AMD . Excess VEGF mediator retinal neovascularization retinal pathological change `` wet '' AMD . Intraocular injection anti-VEGF antibody standard care `` Wet '' AMD . Several publication , include Lim et al , show careful monitoring visual acuity retina patient wet AMD , progression , long-term adverse consequence delay initiation anti-VEGF therapy 4 week . The patient anti-VEGF therapy initiate . The patient monitor monthly interval , 3 month , indication administration anti-VEGF injection . Since establish animal model AMD , L-DOPA good safety profile healthy volunteer patient Parkinson 's disease , Investigators propose prospective experiment determine safety tolerability L-DOPA , population patient AMD . The participant make aware potential side effect L-DOPA , list Informed Consent , consent process . Adverse event elicit question participant visit . The participant also advise call site , medical problem visit . The Investigators also use study examine whether L-DOPA positive effect visual acuity pathologic retinal change `` wet '' AMD . The parameter evaluate best correct ETDRS visual acuity , macular thickness spectral domain optical coherence tomography ( SD OCT ) , new blood ( hemorrhage ) direct retinal examination , subjective decrease vision . Treatments : Patients receive open label , commercially available carbidopa-levodopa 25-100 mg , one tablet daily hs one month , follow one tablet dose TID ( three time daily ) , morning , supper h one month , follow two tablet dose three time daily , morning , supper h one month ( 100-600 mg levodopa daily ) . This equivalent low moderate dos carbidopa-levodopa patient Parkinson 's disease ( daily dose levodopa 200-800 mg ) . Patients enter study complete Study 001 receive one month dose receive Study 001 , one month dose high dose receive Study 001 . Examples : 1 . If patient receive carbidopa-levodopa 25-100 mg daily Study 001 , receive one month treatment 3 daily dos carbidopa-levodopa . 2 . If patient receive carbidopa-levodopa 25-100 mg TID Study 001 , receive one month carbidopa-levodopa 25-100 mg TID , follow one month carbidopa-levodopa 25-100 mg , 2 tablet TID . Each patient receive injection anti-VEGF medication day carbidopa-levodopa dosing begin study . Each patient evaluate monthly ( 25-35 day ) interval inject , base upon criterion list , base clinical practice standard care . Criteria anti-VEGF injection All patient least one anti-VEGF intraocular injection prior enter study . Additional injection base : monthly evaluation ETDRS visual acuity ( decrease 5 letter previous visit ) ; increase macular thickness ( compare normal previous visit measure SD OCT ; new blood ( hemorrhage ) direct retinal examination ; subjective decrease vision . If criterion meet , , opinion Ophthalmologist , patient require anti-VEGF therapy , patient anti-VEGF intraocular injection . If none criterion meet visit 2 , 3 4 , patient agreement , anti-VEGF injection do , patient reevaluate 1 month . The study end Visit 5 , patient begin standard care treatment anti-VEGF injection . Patients complete Study 0001 , Short term effect carbidopa-levodopa Neovascular AMD , eligible enroll current study , Study 0002 , Proof Concept Dose Ranging Study carbidopa-levodopa Neovascular AMD . Number subject : 52 complete Duration : 112 day treatment . Primary Endpoint : A statistically significant improvement ( 5 letter ) carbidopa-levodopa treatment ETDRS visual acuity . Measurements Activities : 1 . Informed Consent Baseline ; 2 . Ophthalmic history comprehensive eye examination ; include visual acuity , wear prescription lens , use EDTRS chart , eye prior randomization , ophthalmoscopic examination , SD OCT ; 3 . Repeat assessment visual acuity use EDTRS chart , ophthalmoscopic examination , SD OCT monthly visit ; 4 . Demographics Baseline ; 5 . Medical History , Vital Signs Physical Examination Baseline ; 6 . ECG , CBC , Chem 20 HbA1C Baseline ; 7 . Dispense study medication visit 2 , 3 4 ; 8 . Pill count visit 3 , 4 5 ; 9 . Non-directed assessment adverse event visit , include classification severity , seriousness body system . 10 . Concomitant medication visit . 11 . If patient baseline evaluation Study 001 , use baseline evaluation study . Statistics : Descriptive statistic generate , minimum , ETDRS visual acuity , central retinal thickness , amount intraretinal subretinal fluid presence hemorrhage . Within patient trajectory outcomes plot , incorporate information dose duration . Due small sample size , model-based analysis consider exploratory . Analysis Variance may conduct relate logarithm dose duration treatment outcomes list .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<criteria>1 . A diagnosis AMD choroidal neovascularization ( CNV ) one eye ; 2. . Not previously treat antiVEGF injection ; b . On antiVEGF injection least 3 month , meet criteria repeat injection ; c. Patients , complete Study 001 , may enter trial point initiation month treatment dose carbidopalevodopa , receive Study 001 ; 3 . Normal dry AMD grade second eye ; 4 . Willingness maintain AREDS vitamin supplement throughout study , remain supplement duration study , take prior study ; 5 . Informed Consent Baseline . 1 . Any current use LDOPA contain medication dopamine agonist medication , plan use agent , except study medication , study ; 2 . Concurrent use monoamine oxidase ( MAO ) inhibitor ; 3 . Any eye condition , disease , history trauma either eye , impair vision , except cataract cataract surgery ; 4 . BCVA worse 20/160 good eye ; 5 . Wet AMD second eye ; 6 . Neurologic condition impair vision ; 7 . Parkinson 's Disease ; 8 . Significant orthostatic hypotension , define drop systolic blood pressure , immediately upon change supine stand position , &gt; 19 mmHg , symptomatic drop systolic blood pressure , immediately upon change supine stand position ; 9 . Significant ECG abnormality , judge Investigator ; 10 . Estimated glomerular filtration rate ( eGFR ) &lt; 20 ml/min ; 11 . Liver enzymes &gt; 3 X upper limit normal ; 12 . HbA1C &gt; 9.0 ; 13 . Any significant lab abnormality , judge Investigator ; 14 . Women childbearing potential ; 15 . Known retinal hemorrhage ; 16 . Subjects fluent English .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>L-DOPA</keyword>
	<keyword>GPR143</keyword>
	<keyword>PEDF</keyword>
	<keyword>VEGF</keyword>
</DOC>